Sep 13, 2022 / 01:10PM GMT
James Patrick Quigley - Morgan Stanley, Research Division - Equity Analyst
Good morning, everyone. I am James Quigley, European Pharma and Biotech analyst at Morgan Stanley. It is my pleasure to welcome you all to this session with MorphoSys. Today, we are joined by CEO, Jean-Paul Kress.
Just before we kick off, I need to read the disclosure statement. So for important disclosures, please Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. So with that, over to Jean-Paul for a quick 2 minute intro set theme.
Jean-Paul Kress - MorphoSys AG - Chairman of Management Board, MD & CEO
Thank you for having us. Great to be here. At MorphoSys, we are trying to change the standard of care in hematology oncology. We have transformed the company over the last 3 years to make sure that we have a late-stage pipeline with assets in
MorphoSys AG at Morgan Stanley Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
